Vir Biotechnology, Inc. $VIR Shares Acquired by Candriam S.C.A.

Candriam S.C.A. increased its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 10.1% in the 1st quarter, Holdings Channel reports. The firm owned 1,135,763 shares of the company’s stock after purchasing an additional 104,100 shares during the period. Candriam S.C.A.’s holdings in Vir Biotechnology were worth $10,176,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after buying an additional 1,390 shares during the last quarter. CWM LLC raised its holdings in shares of Vir Biotechnology by 23.0% during the fourth quarter. CWM LLC now owns 8,804 shares of the company’s stock valued at $53,000 after acquiring an additional 1,646 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Vir Biotechnology by 7.8% during the fourth quarter. ProShare Advisors LLC now owns 23,525 shares of the company’s stock valued at $142,000 after acquiring an additional 1,705 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Vir Biotechnology by 1.0% in the second quarter. Rhumbline Advisers now owns 228,949 shares of the company’s stock valued at $1,154,000 after acquiring an additional 2,300 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its position in shares of Vir Biotechnology by 1.0% in the fourth quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock valued at $1,572,000 after acquiring an additional 2,515 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on VIR shares. Wall Street Zen downgraded Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Morgan Stanley raised their price target on shares of Vir Biotechnology from $23.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, June 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday. Finally, Leerink Partners upped their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the sale, the director owned 21,216 shares in the company, valued at $200,491.20. The trade was a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Vicki L. Sato sold 22,000 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $10.05, for a total value of $221,100.00. Following the completion of the transaction, the director directly owned 1,078,391 shares in the company, valued at approximately $10,837,829.55. This trade represents a 2.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,579 shares of company stock valued at $254,922 over the last quarter. 2.90% of the stock is currently owned by company insiders.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $9.96 on Monday. The firm has a 50 day simple moving average of $9.37 and a 200-day simple moving average of $8.63. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -3.18 and a beta of 1.62. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $11.66.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.84). Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. The firm had revenue of ($0.03) million for the quarter, compared to analysts’ expectations of $55.49 million. During the same period in the previous year, the firm posted ($0.88) EPS. Equities analysts expect that Vir Biotechnology, Inc. will post -1.81 earnings per share for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.